Biologica Technologies is debuting initial clinical data from spinal applications using its ProteiOS® growth factor derived from minimally manipulated allogeneic bone marrow. ProteiOS comprises angiogenic, mitogenic and osteoinductive proteins and what is reportedly the highest amount of non-recombinant BMP-2, and is designed for use with a surgeon’s preferred FDA-cleared scaffold.
ProteiOS entered limited launch in 4Q17, and is now available throughout the U.S.
Biologica Technologies is debuting initial clinical data from spinal applications using its ProteiOS® growth factor derived from minimally manipulated allogeneic bone marrow. ProteiOS comprises angiogenic, mitogenic and osteoinductive proteins and what is reportedly the highest amount of non-recombinant BMP-2, and is designed for use with a...
Biologica Technologies is debuting initial clinical data from spinal applications using its ProteiOS® growth factor derived from minimally manipulated allogeneic bone marrow. ProteiOS comprises angiogenic, mitogenic and osteoinductive proteins and what is reportedly the highest amount of non-recombinant BMP-2, and is designed for use with a surgeon’s preferred FDA-cleared scaffold.
ProteiOS entered limited launch in 4Q17, and is now available throughout the U.S.
Copy to clipboard 
